Share
))
HBO and The Ringer's Bill Simmons hosts the most downloaded sports podcast of all time, with a rotating crew of celebrities, athletes, and media staples, as well as mainstays like Cousin Sal, Joe House, and a slew of other friends and family members who always happen to be suspiciously available.
…
continue reading
Manage episode 513240004 series 3692609
Content provided by Roger Musa, MD, Roger Musa, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Roger Musa, MD, Roger Musa, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this episode of Hospital Medicine Unplugged, we untangle type 1 vs type 2 NSTEMI—different mechanisms, different playbooks, different outcomes—and why hospital factors often tip the scales for type 2.
We set the stage fast:
• Type 1 NSTEMI = atherothrombosis—plaque rupture/erosion → thrombus. Classic chest pain, ischemic ECG, higher use of angiography/PCI, and evidence-based cardioprotective therapy (aspirin + P2Y12, anticoagulation, high-intensity statin, beta-blocker). Protocols are tight and fast.
• Type 2 NSTEMI = supply–demand mismatch—no acute coronary thrombosis. Precipitants are hospital triggers: sepsis, anemia, hypoxia, tachyarrhythmia, perioperative stress, hemodynamic instability. Patients are older, multimorbid, with atypical symptoms and non-specific ECGs. Pathway variability and fragmentation are common—especially off cardiology services.
Diagnosis without derailment:
• Both need troponin rise/fall + ischemia, but context is king. Type 1 often shows larger, quicker deltas and focal wall-motion loss; type 2 shows modest troponin, diffuse stressors, and may lack a culprit lesion.
• When uncertain, lean type 1 to avoid undertreatment—then reclassify as data clarifies.
Management that matches mechanism:
• Type 1: run the ACS bundle—DAPT, anticoagulation, high-intensity statin, early invasive strategy for high-risk, plus ACEi/ARB, MRA when indicated.
• Type 2: treat the trigger first—oxygenation, rate/rhythm control, volume/pressure optimization, fix anemia/infection. Antithrombotics are not one-size-fits-all; reserve revascularization for proven obstructive CAD or ongoing ischemia. Start/optimize statin, beta-blocker, aspirin when CAD is present or likely. Plan CAD evaluation (often outpatient) once stable.
Why type 2 fares worse:
• Higher in-hospital and 1-year mortality, driven by comorbidity and illness severity, not stentable lesions.
• Undertreatment and delays: less cardiology involvement, fewer invasive evaluations, and variable secondary prevention despite frequent underlying CAD.
Close the gap—hospital moves that matter:
Create a type 2 NSTEMI pathway: trigger checklists (sepsis/anemia/hypoxia/tachyarrhythmia), hemodynamic targets, and early echo.
Default cardiology consult for diagnostic clarification and CAD strategy.
Order sets that separate type 1 antithrombotic bundles from type 2 trigger-first care, with guardrails on DAPT/anticoagulation.
Secondary prevention audit: statin/beta-blocker/aspirin started when CAD present or suspected; deprescribe when risk > benefit.
Service-agnostic timers for serial ECG/hs-troponin and for escalation if pain/ischemia persists.
Discharge plan for type 2: trigger control, meds reconciliation, outpatient CAD testing, and close follow-up.
Bottom line: Type 1 is a coronary emergency; type 2 is a circulatory stress test you’re failing. Match the treatment to the mechanism, standardize the inpatient pathway for type 2, and you’ll cut noise, delays, and mortality.
116 episodes
